Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

South Korea CDC Cuts Plan To Vaccinate Children Against Hepatitis B

This article was originally published in PharmAsia News

Executive Summary

The South Korean administration has reneged on a promise to provide 90 percent support for a national vaccination program to protect children against hepatitis B

You may also be interested in...



Novartis Pharma President Marie-France Tschudin On Inclisiran, Launches And More

Tschudin talked to Scrip about taking over as Novartis Pharmaceuticals president, why inclisiran is different from marketed PCSK9 inhibitors and prioritizing investment behind multiple new launches.

Celebrity Takes Role In US FDA Study Of Rx Drug Endorsements

Agency hasn't named the celebrity that will participate in the study on the impact that celebrity and non-celebrity endorsements have on consumer perceptions about Rx drugs.

Vyondys 53 Clinical Development Timeline

Chronicle of the development and review of Sarepta’s golodirsen for treatment of Duchenne muscular dystrophy patients with a genetic mutation amenable to exon 53 skipping.

UsernamePublicRestriction

Register

SC073246

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel